Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression.
Hepatotropic viruses induced hepatitis progresses much faster and causes more liver- related health problems in people co-infected with human immunodeficiency virus (HIV). Although treatment with antiretroviral therapy has extended the life expectancy of people with HIV, liver disease induced by hepatitis B virus (HBV) and hepatitis C virus (HCV) causes significant numbers of non-acquired immune deficiency syndrome (AIDS)-related deaths in co-infected patients. In recent years, new insights into the mechanisms of accelerated fibrosis and liver disease progression in HIV/HCV and HIV/HBV co-infections have been reported. In this paper, we review recent studies examining the natural history and pathogenesis of liver disease in HIV-HCV/HBV co-infection in the era of direct acting antivirals (DAA) and antiretroviral therapy (ART). We also review the novel therapeutics for management of HIV/HCV and HIV/HBV co-infected individuals.
['Ganesan|Murali|M|', 'Poluektova|Larisa Y|LY|', 'Kharbanda|Kusum K|KK|', 'Osna|Natalia A|NA|']
D000998:Antiviral Agents D060085:Coinfection D015897:Comorbidity D018450:Disease Progression D004359:Drug Therapy, Combination D006678:HIV D015658:HIV Infections D016174:Hepacivirus D006509:Hepatitis B D006515:Hepatitis B virus D006526:Hepatitis C D006801:Humans D008099:Liver
Human immunodeficiency virus Treatment Hepatitis B virus Hepatitis C virus Fibrosis Stiffness